drugset / Trial / NCT04910815

Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.

NCT04910815

Unknown 150 enrolled Atmo Biosciences Pty Ltd
RandomizedCrossoverSingle-blindDiagnostic

Summary

The purpose of this study is to determine if the gas-sensing capsule can be used to identify increased numbers and a change of the composition of microbiota or microorganisms in the gut to assess small intestinal dysbiosis

Timeline

Start
2021-07-14
Primary completion
2024-06-01
Completion
2024-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rifaximin Other / unclassified 550 g